Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23843790 | 0.81 | HTR2A (0.44) | HTR2AHTR2CHRH1 | |
| SCHEMBL10238629 | 0.81 | HTR2A (0.47) | HTR2AHTR2CHRH1 | |
| SCHEMBL6448475 | 0.78 | HTR2A (0.43) | HTR2AHTR2CHTR2BPDPK1OPRM1 | |
| SCHEMBL15145778 | 0.78 | HTR2A (0.43) | HTR2AHTR2CHTR2BPDPK1OPRM1 | |
| SCHEMBL9633656 | 0.78 | HTR2A (0.58) | HTR2AHTR2CHRH1 | |
| SCHEMBL8746509 | 0.78 | HTR2A (0.52) | HTR2AHTR2CHTR2BPRCPPDPK1 | |
| SCHEMBL21259158 | 0.77 | PDPK1 (0.44) | HTR2AHTR2CHTR2BPDPK1HRH1 | |
| SCHEMBL10188319 | 0.77 | HTR2A (0.48) | HTR2AHTR2CPRCPPDPK1OPRM1 | |
| SCHEMBL14169739 | 0.75 | MAOA (0.44) | HTR2AHTR2CALDH1A1MAPTHRH1 | |
| SCHEMBL59871 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3815689-A1 | ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | National University Corporation Hokkaido University (JP) | 2021-05-05 | — | — | EP | disclosed |
| US-20200339565-A1 | PRODRUG SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2020-10-29 | — | — | US | disclosed |
| US-20190248785-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2019-08-15 | — | — | US | disclosed |
| EP-2620436-B1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO (JP) | 2018-05-09 | — | — | EP | disclosed |
| EP-2444400-B1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO (JP) | 2018-03-28 | — | — | EP | disclosed |
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| US-9815835-B2 | Substituted polycyclic carbamolypyridone derivative | SHIONOGI & CO., LTD. (JP) | 2017-11-14 | — | — | US | disclosed |
| US-9758515-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | SHIONOGI & CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-20160368921-A1 | SUBSTITUTED POLYCYCLIC CARBAMOLYPYRIDONE DERIVATIVE | SHIONOGI & CO (JP) | 2016-12-22 | — | — | US | disclosed |
| US-9505783-B2 | Method of producing pyrone and pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2016-11-29 | — | — | US | disclosed |
| US-8987441-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | SHIONOGI & CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| US-20150065485-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO (JP) | 2015-03-05 | — | — | US | disclosed |
| US-20150031876-A1 | METHOD FOR PRODUCING PYRONE AND PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2015-01-29 | — | — | US | disclosed |
| US-8927710-B2 | Substituted polycyclic carbamoylpyridone derivative | SHIONOGI & CO., LTD. (JP) | 2015-01-06 | — | — | US | disclosed |
| US-8865907-B2 | Method of producing pyrone and pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2014-10-21 | — | — | US | disclosed |
| US-20120184734-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| EP-2444400-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | Shionogi&Co., Ltd. (JP) | 2012-04-25 | — | — | EP | disclosed |
| EP-2412709-A1 | PROCESS FOR PRODUCING PYRONE AND PYRIDONE DERIVATIVES | Shionogi & Co., Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20120022251-A1 | METHOD OF PRODUCING PYRONE AND PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| WO-2010147068-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | 塩野義製薬株式会社 (JP) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368921-A1 | SUBSTITUTED POLYCYCLIC CARBAMOLYPYRIDONE DERIVATIVE | CNBP, ZC3HAV1, DPP4 | HTR2A 3829/4885HTR2C 3425/4885HTR2B 3507/4885 |
| US-20150065485-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | CNBP, ZC3HAV1, DPP4 | HTR2A 3825/4885HTR2C 3531/4885HTR2B 3614/4885 |
| US-20150031876-A1 | METHOD FOR PRODUCING PYRONE AND PYRIDONE DERIVATIVES | PNPO, PDXK, CYP3A5 | HTR2A 1536/4885HTR2C 1662/4885HTR2B 1730/4885 |
| US-20120022251-A1 | METHOD OF PRODUCING PYRONE AND PYRIDONE DERIVATIVES | PNPO, PDXK, CYP3A5 | HTR2A 1427/4885HTR2C 1594/4885HTR2B 1666/4885 |
| US-20120184734-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | CNBP, ZC3HAV1, DPP4 | HTR2A 3825/4885HTR2C 3531/4885HTR2B 3614/4885 |
| US-20190248785-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | HTR2A 3244/4885HTR2C 2588/4885HTR2B 3097/4885 |
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | HTR2A 3244/4885HTR2C 2588/4885HTR2B 3097/4885 |
| US-20200339565-A1 | PRODRUG SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | PREP, UNG, DPP4 | HTR2A 3231/4885HTR2C 2630/4885HTR2B 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.